Le Lézard
Classified in: Health, Covid-19 virus

Entourage Launches Unique Medical Cannabis Marketplace "Syndicate" Offering Premium Craft Products From Collective of In-House and Third-Party Micro Producers

TORONTO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Entourage Health Corp. (TSX-V:ENTG) (OTCQX:ETRGF) (FSE:4WE) ("Entourage" or the "Company"), a Canadian producer and distributor of award-winning cannabis products is pleased to announce the launch of Syndicate a direct-to-patient medical cannabis marketplace showcasing a portfolio of premium craft cannabis products sourced both in-house and from third-party micro-cultivators and producers. The Company is one of the first to launch a medical-marketplace collective of craft producers.

Syndicate complements the Company's popular medical platform Starseed Medicinal which specializes as a medical cannabis provider to clients with insurance benefits coverage. With Syndicate, patients without insurance coverage can access a comprehensive catalogue of cannabis products, formats, and brands at a competitive price point. A unique model that offers an assortment of products from various producers, including partnerships with Greenseal Cannabis, Sitka Micro, Premium 5 and QWest Cannabis; a collective of micro-cultivators looking to distribute small-batch brands into the medical channel.

"Launching Syndicate as a supplementary medical marketplace has been a long-time passion project for many of us at Entourage because it reinforces our commitment to providing optimal patient care with access to locally produced, quality cannabis products within a framework of affordability," said Nikki Thomas, Marketing Director, Entourage. "Additionally, in supporting craft producers with a medical outlet to share their unique offerings with our patients, we are taking our medical business to the next level. Our Syndicate clients will have the same patient-centric services currently offered to our Starseed clients ? all rooted in innovation, technology and education. Empowering our patients with a seamless online process and access to world-class customer service provides for a safe and responsible entry-point."

"The original purpose for launching our Company in 2013 harkens back to our deep-seeded belief that medical cannabis as a wellness option should be made available to all eligible Canadians and we are proud to be partnering with these micro-cultivators and licensed producers who share in this mission," said George Scorsis, CEO and Executive Chairman, Entourage. "With Syndicate, we are returning to our roots with access to medical cannabis at the heart of our purpose. We continue to advocate for cannabis medicine to be an insured benefit, but we know the reality is that not all our clients have access and this channel is dedicated to those patients."

Canadian medical patients in Ontario (with more provinces to be added) can now register as Syndicate patients here. With more than 50 products from over five local producers expected to be available, patients may select unique products such as infused pre-rolls, topical compounds, oils, vapes, edibles, dried flower products and soon, cannabis-infused beverages ?TeaPot'. Additionally, Syndicate offers a compassionate pricing program and fast and convenient shipping options.

Syndicate will handle the customer service, online payments and fulfillment as Entourage continues to bring many other partners into the fold in the coming months.

Visit Entourage's website here to access the latest Company updates.

About Entourage Health Corp.

Entourage Health Corp. is the publicly traded parent company of Entourage Brands Corp. (formerly WeedMD RX Inc.) and CannTx Life Sciences Inc., licence holders producing and distributing cannabis products for both the medical and adult-use markets. The Company owns and operates a state-of-the-art hybrid greenhouse and processing facility located on 158-acres in Strathroy, ON; a fully licensed 26,000 sq. ft. Aylmer, ON processing facility, specializing in cannabis extraction; and a micropropagation, tissue culture and genetics centre-of-excellence in Guelph, Ontario. With its Starseed Medicinal medical-centric brand and marketplace, Entourage has an industry-first, exclusive partnership with LiUNA, the largest construction union in Canada, who together with employers and other union groups, facilitate access for insured medical patients. With the launch of Syndicate, the Company now hosts another unique medical marketplace that offers patients a collective of Canadian micro-cultivators' products, along with the Company's family of brands. Entourage's elite adult-use product portfolio includes Color Cannabis, Saturday Cannabis and Royal City Cannabis Co.? sold across eight provincial distribution agencies. It is the exclusive Canadian producer and distributor of award-winning U.S.-based wellness brand Mary's Medicinals sold in both medical and adult-use channels. Under a collaboration with The Boston Beer Company subsidiary, Entourage is also the exclusive distributor of cannabis-infused beverages ?TeaPot' in Canada, which launched in select provinces summer 2022.

For more information, please visit us at: www.entouragehealthcorp.com

Follow Entourage and its brands on: LinkedIn

Twitter: Entourage, Color Cannabis, Saturday Cannabis, Starseed, Royal City Cannabis Co. & Syndicate

Instagram: Entourage, Color Cannabis, Saturday Cannabis, Starseed, Royal City Cannabis Co. & Syndicate

For further information, investor or media inquiries, please contact:

Marianella delaBarrera
SVP, Communications & Corporate Affairs

Forward Looking Information: This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation which are based upon Entourage's current internal expectations, estimates, projections, assumptions and beliefs and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy.

The forward-looking information in this news release is based upon the expectations, estimates, projections, assumptions and views of future events which management believes to be reasonable in the circumstances. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of fact. Forward-looking information necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; loss of markets; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally; the ability of Entourage to implement its business strategies; the COVID-19 pandemic; competition; crop failure; and other risks.

Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, Entourage does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for Entourage to predict all such factors. When considering this forward-looking information, readers should keep in mind the risk factors and other cautionary statements in Entourage's disclosure documents filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in the disclosure documents could cause actual events or results to differ materially from those described in any forward-looking information.


These press releases may also interest you

at 18:30
The global endocrinology drugs market size is set to grow by USD 36551.24 million from 2022 to 2027, according to Technavio. The growth momentum of the market will accelerate at a CAGR of 7.82% during the forecast period. This report provides...

at 18:05
Puma Biotechnology, Inc. , a biopharmaceutical company, presented updated findings from the Translational Breast Cancer Research Consortium (TBCRC) Trial 022 at the ongoing 2022 San Antonio Breast Cancer Symposium in San Antonio, Texas. The poster...

at 18:00
The global smoking cessation and nicotine de-addiction market size is set to grow by USD 24,529.75 million from 2022 to 2027, according to Technavio. The growth momentum of the market will accelerate at a CAGR of 12.59% during the forecast period....

at 17:44
We need to address health inequities and promote positive mental health for people across the country, particularly for those who face disproportionate challenges accessing mental health supports due to racism and discrimination or because of their...

at 17:05
Dr. Shervin Naderi, the founder of The Naderi Center for Plastic Surgery & Dermatology in Virginia and Maryland, has been chosen again as one of Washingtonian Magazine's Top Doctors for 2022. Dr. Naderi was nominated by his colleagues as a Top Doctor...

at 17:00
CB Insights today named harrison.ai to its fourth-annual Digital Health 150, showcasing the 150 most promising private digital health companies of 2022. "From reimagining clinical care, to leveraging tech like AR/VR to improve surgical training, this...

News published on 27 september 2022 at 07:30 and distributed by: